Biocon

Focus: Biocon is a fully integrated biotechnology company headquartered in Bangalore, India, with a diversified portfolio spanning oncology, neurology, cardiovascular, nephrology, and infectious diseases. The company operates across branded generics, biosimilars, and novel biologics.

Oncology Neurology Cardiovascular Nephrology

Profile data last refreshed 22h ago · AI intelligence enriched 2w ago

Open Jobs

About Biocon

AI assessmentNot Hiring

No open roles listed right now. Follow Biocon to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

6 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

OXCARBAZEPINE

Partial-onset seizures in patients ≥6 years

$5M Part D

Post-LOE

Dominant revenue driver (48% of company revenue) but generic market compression limits growth; major patent cliff risk.

Help build intelligence for Biocon

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a global pipeline with 20 active programs across Phase 1–3, including late-stage oncology (PERT-IJS in HER2+ breast cancer Phase 3) and immunology candidates (Itolizumab, Bmab series).
Exposure to India-based biotech scale-up model with established manufacturing and regulatory infrastructure across multiple geographies.
Diversified therapeutic portfolio reduces single-drug dependency and creates career paths across oncology, metabolic disease, and immunology.

Watch Out For

Extreme revenue concentration: 48% from a single post-LOE generic (Oxcarbazepine), creating significant margin pressure and restructuring risk.
Limited hiring activity (0 active job postings at time of analysis) and minimal disclosed H1B sponsorship data suggest constrained near-term growth.

Generated by Claude from Biocon's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

DYRENIUM

Edema in CHF, cirrhosis, nephrotic syndrome

$283K Part D

LOE Approaching

Established diuretic nearing LOE; minimal revenue contribution ($283K) reflects shrinking utility in modern heart failure management.

DAPTOMYCIN

Skin/soft-tissue infections, endocarditis, pneumonia

$64K Part D

Post-LOE

Generic antibiotic with negligible Part D spending; limited exclusivity and commodity pricing.

POSACONAZOLE

Invasive Aspergillus prophylaxis in immunocompromised patients

$21K Part D

Post-LOE

Niche antifungal with specialized indication; consistent but modest revenue reflects limited patient population.

PRAVASTATIN SODIUM

Clinically evident coronary heart disease

Post-LOE

Generic statin with no reported Part D spending; commodity competition in mature cholesterol-lowering market.

JOBEVNE

VEGF-directed antibody (oncology indication pending)

Launch

Biosimilar bevacizumab at market entry; represents shift toward high-value biologics but early-stage revenue contribution.

RIVAROXABAN

Factor Xa inhibition (thromboembolism prevention)

Post-LOE

Generic anticoagulant in highly competitive market; limited differentiation and pricing pressure.

Pipeline & Clinical Trials

The Mycophenolate Pregnancy Registry

Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases

N/A

Bmab 1200

Moderate to Severe Chronic Plaque Psoriasis

Phase 1

Clinical Trials (1)

NCT06738277This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).

Phase 1

Bmab1800

Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)

Phase 1

Clinical Trials (1)

NCT07581509Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma

Phase 1

EQ001

Asthma

Phase 1

Biocon's Human Insulin R U-500

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05413863Comparison of the Pharmacokinetic and Pharmacodynamic Properties of Biocon's Insulin R U-500 With Humulin® R U-500 (US Reference Product) in Healthy Subjects

Phase 1

Biocon Insulin N

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT04022304Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N

Phase 1

Biocon Insulin R

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT04022317Comparision of Pharmacokinetics(PK) and Pharmacodynamics(PD) of Biocon Insulin R and Humulin® R

Phase 1

IN-105

Type 2 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT03392961Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD

Phase 1

Tregopil

Type 1 Diabetes Mellitus (T1DM)

Phase 1

Clinical Trials (1)

NCT04141423Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil

Phase 1

Bmab 1000

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT05323708Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS

Phase 1

IN-105

Type 1 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01035801Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients

Phase 1

Bmab1700

Melanoma

Phase 1

Clinical Trials (1)

NCT07476326Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Phase 1

Itolizumab [Bmab 600]

Lupus Erythematosus

Phase 1

Clinical Trials (1)

NCT04128579Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

Phase 1

Humulin ®70/30

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT04022291Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30

Phase 1

Bmab3000

Healthy Male Participants

Phase 1

Clinical Trials (1)

NCT07299955A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers

Phase 1

EQ001

Acute-graft-versus-host Disease

Phase 1/2

Clinical Trials (1)

NCT03763318A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD

Phase 1/2

Tucatinib 150 MG

HER2-positive Breast Cancer

Phase 2

Itolizumab IV infusion

Acute Respiratory Distress Syndrome

Phase 2

Clinical Trials (1)

NCT04475588Efficacy and Safety of Itolizumab in COVID-19 Complications

Phase 2

Insulin Tregopil

Type2 Diabetes Mellitus

Phase 2/3

Clinical Trials (1)

NCT03430856Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients

Phase 2/3

Stelara

Moderate to Severe Chronic Plaque Psoriasis

Phase 3

Clinical Trials (1)

NCT05335356Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase 3

Itolizumab

Graft Versus Host Disease

Phase 3

Humira 40 MG in Prefilled Syringe

Moderate Chronic Plaque Psoriasis

Phase 3

Bmab 1000

Postmenopausal Women With Osteoporosis

Phase 3

Clinical Trials (1)

NCT05345691Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis

Phase 3

EQ001

Coronavirus

Phase 3

Clinical Trials (1)

NCT04605926A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

Phase 3

PERT-IJS plus trastuzumab, carboplatin and docetaxel

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

Phase 3

Clinical Trials (1)

NCT06038539Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Phase 3